Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
University of Edinburgh British Heart Foundation |
---|---|
Information provided by: | University of Edinburgh |
ClinicalTrials.gov Identifier: | NCT00722215 |
The number of people with kidney problems is increasing rapidly, related in part to the increasing prevalence of diabetes. Patients with kidney problems tend to have protein leaking into the urine (proteinuria). Both proteinuria and the kidney disease itself are associated with an increased risk of heart disease. Reducing proteinuria is an important treatment goal in people with kidney problems. Endothelin is a chemical produced both by blood vessels and the kidney. Higher than normal levels of endothelin are thought to contribute to progression of kidney disease and proteinuria. By using drugs that block the effects of endothelin ('endothelin receptor antagonists') we can hopefully reduce both of these. The purpose of the study is to ascertain whether endothelin receptor antagonists improve kidney function and reduce proteinuria more so than other commonly used drugs.
Condition | Intervention | Phase |
---|---|---|
Chronic Kidney Disease Proteinuria |
Drug: BQ-123 (selective endothelin A receptor antagonist) Drug: 0.9 % saline Drug: Nifedipine |
Phase I |
Study Type: | Interventional |
Study Design: | Basic Science, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Placebo Control, Crossover Assignment, Efficacy Study |
Official Title: | The Systemic & Renal Effects of Endothelin Receptor Antagonism in Proteinuric Nephropathy |
Enrollment: | 22 |
Study Start Date: | May 2006 |
Study Completion Date: | December 2007 |
Primary Completion Date: | November 2007 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Placebo Comparator
Placebo control arm of study
|
Drug: 0.9 % saline
Single 15ml 0.9% saline infused for 15 mins as placebo control
|
2: Experimental
BQ-123 arm of study
|
Drug: BQ-123 (selective endothelin A receptor antagonist)
Single dose of BQ-123 given at a dose of 1000 nmol/min for 15 min intravenously.
|
3: Active Comparator
Nifedipine arm of study
|
Drug: Nifedipine
Single dose of nifedipine 10 mg given orally as active control
|
Response to ETA Receptor Antagonism/Nifedipine/Placebo Prior to the study visit subjects will be asked to refrain from alcohol for 24 hours. Tea and coffee will not be permitted for at least 12 hours before each visit. Studies will be conducted in a quiet, temperature-controlled room.
On arrival at the Clinical Research Centre on the study day, a brief medical enquiry and examination will confirm the ongoing suitability of the subject for the study. An intravenous cannula will be inserted into the antecubital fossa of each arm. We have developed a basic protocol described fully in our previous studies that allows us to measure systemic haemodynamics by the well validated technique of bioimpedance and renal function by standard para-aminohippurate (PAH; renal blood flow) and inulin (glomerular filtration rate) clearance studies.
Urinary protein excretion will be measured by collecting urine over 30 minute time periods. To ascertain the contribution of renal haemodynamics to any change in protein excretion renal blood flow and glomerular filtration rate will be measured. In addition, blood and urine will also be assayed for sodium, creatinine and osmolality to allow calculation of fractional excretion of sodium and free water clearance.
Systemic haemodynamic monitoring will be performed at 15 minute intervals during drug/placebo administration and at 30 minute intervals outwith these periods.
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United Kingdom, Scotland | |
Clinical Research Centre, Western General Hospital | |
Edinburgh, Scotland, United Kingdom, EH4 2XU |
Principal Investigator: | Neeraj Dhaun, MBChB | The University of Edinburgh |
Study Director: | David J Webb, MD | The University of Edinburgh |
Responsible Party: | The University of Edinburgh ( Dr Neeraj Dhaun ) |
Study ID Numbers: | 2006/WCRC/02, PG/05/91, 06/MRE00/12 |
Study First Received: | July 23, 2008 |
Last Updated: | July 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00722215 History of Changes |
Health Authority: | United Kingdom: Research Ethics Committee |
Endothelin antagonist Chronic kidney disease Proteinuria Cardiovascular disease |
Blood pressure Arterial stiffness Endothelial function |
Vasodilator Agents Renal Insufficiency Urination Disorders Kidney Failure, Chronic Calcium Channel Blockers Cardiovascular Agents Nifedipine Signs and Symptoms |
Calcium, Dietary Proteinuria Urologic Diseases Renal Insufficiency, Chronic Kidney Diseases Cyclo(Trp-Asp-Pro-Val-Leu) Kidney Failure |
Vasodilator Agents Renal Insufficiency Molecular Mechanisms of Pharmacological Action Urination Disorders Physiological Effects of Drugs Kidney Failure, Chronic Calcium Channel Blockers Reproductive Control Agents Cardiovascular Agents Nifedipine Pharmacologic Actions |
Membrane Transport Modulators Urological Manifestations Signs and Symptoms Proteinuria Tocolytic Agents Urologic Diseases Renal Insufficiency, Chronic Therapeutic Uses Kidney Diseases Kidney Failure |